<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study defined the clinical features and assessed the prognosis of 47 patients (17 males, 30 females, median age 63 years) with primary nodal marginal zone B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Forty-five per cent had stage IV disease </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0012115'>Hepatitis</z:hpo> C virus serology was positive in 24% </plain></SENT>
<SENT sid="3" pm="."><plain>According to the Follicular <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> International Prognostic Index (FLIPI), 33% were classified as low-risk, 34% as intermediate-risk, and 33% as high-risk </plain></SENT>
<SENT sid="4" pm="."><plain>The 5-year overall survival (OS) was 69% </plain></SENT>
<SENT sid="5" pm="."><plain>In univariate analysis worse OS was associated with: FLIPI (P = 0.02), age &gt; 60 years (P = 0.05) and raised <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase (P = 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>In multivariate analysis, only FLIPI predicted a worse OS (P = 0.02) </plain></SENT>
</text></document>